Six Years of Disease-free Survival After a Second Cord Blood Transplantation for Recurrent Acute Lymphocytic Leukemia in a Child With Down Syndrome

J Pediatr Hematol Oncol. 2024 Jan 1;46(1):e100-e102. doi: 10.1097/MPH.0000000000002794. Epub 2023 Dec 8.

Abstract

Outcomes are extremely poor in Down syndrome-associated acute lymphocytic leukemia, particularly in recurrent cases. A 2-year-old boy with Down syndrome-associated acute lymphocytic leukemia achieved complete remission after standard chemotherapy. However, he experienced recurrence twice in the bone marrow and central nervous system. Salvage treatments included whole-brain/whole-spine irradiation. Thereafter, the patient received a second cord blood transplantation after the reduced-intensity conditioning. The graft was characterized by killer cell immunoglobulin-like receptor ligands mismatch. The patient has subsequently survived for 6.5 years without recurrence. We speculate that killer cell immunoglobulin-like receptor ligand-mismatched cord blood transplantation enhanced the graft-versus-leukemia effect through natural killer cells, and conferred long-term remission.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Child
  • Child, Preschool
  • Chronic Disease
  • Cord Blood Stem Cell Transplantation*
  • Disease-Free Survival
  • Down Syndrome* / complications
  • Down Syndrome* / therapy
  • Graft vs Host Disease*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
  • Receptors, KIR
  • Recurrence
  • Transplantation Conditioning

Substances

  • Receptors, KIR